Indian Heart Journal · 2019 · 23 citations · 39 references
MedicineCardiologyInternal MedicineAcute Care MedicineCardiothoracic SurgeryClinical CardiologyCardiac EmergenciesCardiogenic ShockMyocardial Infarction ComplicationsDelayed PresentationIn-hospital MortalityPost-myocardial Infarction ComplicationsRight Ventricular InfarctionSymptom Onset Timing
OBJECTIVE: Delayed presentation after ST-elevation myocardial infarction (STEMI) and complicated by cardiogenic shock (CS-STEMI) is commonly encountered in developing countries and is a challenging scenario because of a delay in revascularization resulting in infarction of a large amount of the myocardium. We aimed to assess the clinical characteristics, angiographic profile, and predictors of outcome in patients with a delayed presentation after CS-STEMI. METHODS: A total of 147 patients with CS-STEMI with time to appropriate medical care ≥12 h after symptom onset were prospectively recruited at a tertiary referral center. RESULTS: The median time to appropriate care was 24 h (interquartile range 18-48 h). The mean age was 58.7 ± 11.1 years. Left ventricular pump failure was the leading cause of shock (67.3%), whereas mechanical complications accounted for 14.9% and right ventricular infarction for 13.6% of cases. The overall in-hospital mortality was 42.9%. Acute kidney injury [Odds ratio (OR) 8.04; 95% confidence intervals (CI) 3.08-20.92], ventricular tachycardia (OR 7.04; CI 2.09-23.63), mechanical complications (OR 6.46; CI 1.80-23.13), and anterior infarction (OR 3.18; CI 1.01-9.97) were independently associated with an increased risk of mortality. Coronary angiogram (56.5%) revealed single-vessel disease (45.8%) as the most common finding. Percutaneous coronary intervention was performed in 53 patients (36%), at a median of 36 h (interquartile range 30-72) after symptom onset. CONCLUSION: Patients with a delayed presentation after CS-STEMI were younger and more likely to have single-vessel disease. We found a high in-hospital mortality of 42.9%. Appropriate randomized studies are required to evaluate the optimal treatment strategies in these patients.
39
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
Patrick T. O’Gara, Frederick G. Kushner, Deborah D. Ascheim et al. · Circulation · 2012 · 4.7K citations
The Thrombolysis in Myocardial Infarction (TIMI) Trial
New England Journal of Medicine · 1985 · 3.2K citations
Medicine, Cardiology, Surgery +9